Chino Hills, CA, Aug. 09, 2018 (GLOBE NEWSWIRE) -- We are advised by SOHM, Inc. (PINKSHEETS: SHMN) that journalists and other readers should disregard the news release, "SOHM, Inc. Subsidiary Daiichi Sankyo Group Files Its Acute Myeloid Leukemia (AML) Treatment Quizartinib in the US; the FDA Awarded Breakthrough Status for The Drug," issued Thursday, August 9, 2018, over GlobeNewswire.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0012 USD | -14.29% | -17.65% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 0 | |
+25.97% | 661B | |
+26.74% | 566B | |
-6.59% | 352B | |
+18.70% | 332B | |
+3.62% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.34% | 145B |
- Stock Market
- Equities
- SHMN Stock
- News SOHM INC
- NOTICE TO DISREGARD - SOHM, Inc.